Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 55150-382

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pemetrexed (NDC 55150-382). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Pemetrexed Fig1)

A Kaplan-Meier overall survival curve chart showing percentage survival over time in months. Two treatment arms are compared: P+P+C (black line) and P+C (gray line). The chart includes a table below indicating the number of patients at risk at various time points for each treatment arm.*

FDA Label Image

Package Label-principal Display Panel- 100 mg Per Vial (Container Label)

Label for Pemetrexed injection, USP, 100 mg per vial, lyophilized powder for intravenous use. The label includes storage instructions, manufacturer information (AuroMedics Pharma LLC), and cautions indicating cytotoxicity and single-dose vial usage with disposal instructions for unused portions. The label displays the NDC 55150-381-01 and a barcode.*

FDA Label Image

Package Label-principal Display Panel- 100 mg Per Vial (Container Carton)

Label for Pemetrexed for Injection, USP 100 mg per vial, a powder, lyophilized, for intravenous solution. The label includes reconstitution instructions, storage conditions, usage caution as a cytotoxic agent, and distributor information for AuroMedics Pharma LLC. It states the product is a single-dose vial and contains the Auromedics logo.*

FDA Label Image

Package Label-principal Display Panel- 500 mg Per Vial (Container Label)

Pemetrexed for Injection, USP 500 mg per vial label, for intravenous use only. The label includes warnings for cytotoxic agent handling and instructions to discard unused portions. It states the vial contains pemetrexed disodium equivalent to 500 mg pemetrexed with mannitol and pH adjustments. Storage instructions specify 25°C with allowed excursions. Manufactured in India for AuroMedics Pharma LLC, E. Windsor, NJ. NDC 55150-382-01 is visible along with barcode and QR code.*

FDA Label Image

Package Label-principal Display Panel- 500 mg Per Vial (Container Carton)

Label for Pemetrexed 500 mg per vial injection, USP, powder lyophilized for solution, for intravenous use only. The label is for a single-dose vial distributed by AuroMedics Pharma LLC. It includes reconstitution instructions, storage conditions, and a caution indicating it is a cytotoxic agent. The packaging features the Auromedics logo and a barcode.*

FDA Label Image

Package Label-principal Display Panel- 1,000 mg Per Vial (Container Label)

Label for Pemetrexed injection, USP 1,000 mg per vial, lyophilized powder for intravenous use. The single-dose vial label includes storage instructions, manufacturer AuroMedics Pharma LLC, and cautions that the drug is cytotoxic and unused portions should be discarded. The label shows the NDC 55150-383-01 and barcode.*

FDA Label Image

Package Label-principal Display Panel- 1,000 mg Per Vial (Container Carton)

Pemetrexed for Injection, USP 1,000 mg per vial powder label for lyophilized injection by Auromedics Pharma LLC. The label indicates the product is for intravenous use only, single-dose vial, and cautions it as a cytotoxic agent. It includes reconstitution instructions, storage conditions, and distributor information with barcode and NDC 55150-383-01.*

FDA Label Image

Figure 2 (Pemetrexed Fig2)

A survival probability graph comparing Pemetrexed plus Cisplatin (PC) versus Gemcitabine plus Cisplatin (GC) over a 30-month survival time period. The chart includes survival curves with survival probability on the y-axis and survival time in months on the x-axis, accompanied by patient risk counts for each group at various time points.*

FDA Label Image

Figure 3 (Pemetrexed Fig3)

A Kaplan-Meier survival probability curve comparing survival time in months for two treatment groups: Pemetrexed plus Cisplatin (PC) indicated by a solid line and Gemcitabine plus Cisplatin (GC) indicated by a dotted line. The x-axis represents survival time in months up to 30 months, and the y-axis shows survival probability from 0 to 1. Below the graph is a table listing patients at risk for both PC and GC groups at various time points.*

FDA Label Image

Figure 4 (Pemetrexed Fig4)

A survival probability curve comparing treatments Pemetrexed plus Cisplatin (PC) and Gemcitabine plus Cisplatin (GC) over survival time in months. The chart includes a legend for the two treatment groups and a table of patients at risk at various time points for each group, illustrating longitudinal survival data.*

FDA Label Image

Figure 5 (Pemetrexed Fig5)

A line graph displaying survival probability against survival time in months for Pemetrexed and placebo groups. Solid line represents Pemetrexed with generally higher survival probability over time than the dotted placebo line. A table below shows patient counts at risk in both groups at various time points up to 42 months.*

FDA Label Image

Figure 6 (Pemetrexed Fig6)

A Kaplan-Meier survival curve chart comparing survival probability over time (in months) between patients treated with Pemetrexed and those given a placebo. The chart shows two curves with survival probability on the vertical axis and survival time on the horizontal axis, including a table of patients at risk at various time points for both groups.*

FDA Label Image

Figure 7 (Pemetrexed Fig7)

A Kaplan-Meier survival curve comparing survival probability over time (months) between two groups: one treated with Pemetrexed and the other with placebo. The graph includes survival probabilities ranging from 0 to 1 and displays the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 8 (Pemetrexed Fig8)

A survival probability Kaplan-Meier curve comparing Pemetrexed and Placebo groups over time in months. The x-axis represents survival time up to 36 months, and the y-axis shows survival probability from 0 to 1. A table below the x-axis displays the number of patients at risk for each group at various time points.*

FDA Label Image

Figure 9 (Pemetrexed Fig9)

A survival probability Kaplan-Meier curve comparing two groups: Pemetrexed + Cisplatin versus Cisplatin alone, plotted over survival time in months. The chart shows a higher survival probability for the Pemetrexed + Cisplatin group across the timeline. Below the graph, the number of patients at risk in each group is listed at various intervals up to 30 months.*

FDA Label Image

Chemical-structure (Pemetrexed Str)

Chemical structure of Pemetrexed, showing its molecular components including nitrogen-containing rings and carboxylate groups, with sodium and water of hydration indicated.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.